A Surprising Turn in Medical Science
Dr. Sarah Chen had been treating patients with diabetes for nearly fifteen years when she noticed something that would change the way she thought about her work. It started on a quiet Tuesday morning in her clinic, with a patient named Margaret who had been coming to see her for the better part of a decade.
Margaret was seventy-two years old, a retired teacher who had spent thirty-four years in the classroom teaching sixth-grade English. She had the kind of warm, crinkly smile that made everyone in the waiting room feel at ease. But over the years, Sarah had watched Margaret change in small, almost imperceptible ways. At first, it was little things. Margaret would forget appointments, then have to call to reschedule. She would misplace her keys more often than seemed normal. During their conversations, she would sometimes pause mid-sentence, searching for a word that used to come easily.
Sarah had attributed these changes to normal aging at first. After all, everyone slows down a bit as the years pass. But on this particular Tuesday, something was different.
Margaret walked into the exam room with a bounce in her step that had been missing for years. She was carrying a folded newspaper under her arm, and before Sarah could even say hello, Margaret unfolded it with a flourish.
“I finished it,” Margaret announced, her voice carrying a note of triumph. “The whole thing. No help. Not even once.”
Sarah looked down at the newspaper and saw what Margaret was pointing at. It was the Sunday crossword puzzle, the notoriously difficult one that took most people hours to complete, if they could finish it at all. The grid was filled with neat, precise handwriting, every square accounted for.
“I don’t know what’s happening,” Margaret continued, settling into the chair across from Sarah’s desk. “But I finished the Sunday puzzle last week without any help. Last year, I couldn’t even remember where I put my glasses half the time. I was leaving the stove on. My daughter was starting to get worried about me.”
Sarah smiled, but behind her professional calm, her mind was racing. She had seen glimpses of this in other patients over the years. There was Henry, a retired bus driver who had suddenly started remembering his grandchildren’s birthdays again after years of forgetting. There was Patricia, who had called the office to report that she had finally learned how to use her smartphone without calling her son for help every single time.
At the time, Sarah had dismissed these changes as coincidence, maybe a fluke or the natural ebb and flow of cognitive function. But now, with Margaret sitting in front of her, so clearly sharper and more engaged than she had been in years, Sarah couldn’t ignore the pattern any longer.
She pulled up Margaret’s chart on her computer and started scrolling back through years of appointment notes, medication lists, and lab results. And then she saw it.
About two years ago, Margaret’s previous doctor had made a change to her diabetes treatment plan. She had been on metformin, the standard first-line medication for type 2 diabetes, for over a decade. But because she was struggling with weight gain and her blood sugar numbers weren’t quite where they needed to be, the doctor had switched her to a newer class of medication called a GLP-1 agonist.
The timing lined up. The medication change had happened roughly two years ago. Margaret’s cognitive decline had been noticeable before that. But now, two years later, she was solving crossword puzzles that would stump most college graduates.
Sarah couldn’t prove that the medication caused Margaret’s improvement. There were too many other factors at play. But she made a note in Margaret’s chart to continue the medication and to track her cognitive function more carefully in the future. She also started paying closer attention to her other patients who were taking similar drugs.
What Sarah was witnessing would soon become part of one of the most exciting developments in modern medical research. Across the world, in laboratories and universities and hospitals, scientists were beginning to piece together evidence that some of the most common diabetes medications might do something completely unexpected. They might affect the brain in powerful ways, potentially protecting against memory loss, Alzheimer’s disease, and other forms of cognitive decline that affect millions of people worldwide.
This discovery represents a fundamental shift in how we understand the connection between the body and the brain. It’s opening up new possibilities for treating diseases that have long seemed untreatable. And it’s giving hope to millions of patients and their families who are watching, often helplessly, as cognitive decline steals away the people they love.
The Diabetes-Alzheimer’s Connection That Changes Everything
For decades, doctors and researchers noticed something puzzling that they couldn’t quite explain. Over and over again, studies showed that people with type 2 diabetes seemed to develop Alzheimer’s disease at much higher rates than people without diabetes. The numbers were striking. Depending on the study, having diabetes increased the risk of developing Alzheimer’s by anywhere from 50 to 100 percent.
At first, many researchers thought this connection was probably due to the vascular damage that diabetes causes. After all, diabetes damages blood vessels throughout the body, including the tiny, delicate vessels that supply blood to the brain. If those vessels become narrowed or blocked, brain cells don’t get the oxygen and nutrients they need, and they start to die. That could certainly explain why people with diabetes had more cognitive problems as they aged.
But as researchers dug deeper, they discovered something that surprised them. The connection between diabetes and Alzheimer’s was much deeper and more fundamental than just damaged blood vessels.
In the early 2000s, a series of groundbreaking studies revealed that the brains of people with Alzheimer’s disease often show signs of insulin resistance. That is, the brain cells themselves become less responsive to insulin, just like the muscle and liver cells in people with type 2 diabetes. This finding was so striking that some researchers began calling Alzheimer’s “type 3 diabetes.”
To understand why this matters, you have to understand what insulin does in the brain. For a long time, scientists thought insulin’s main job was to help cells absorb glucose from the bloodstream to use as energy. That’s certainly important in muscles and the liver. But in the brain, insulin does much more than that.
Insulin acts like a master regulator, controlling a huge range of functions that brain cells need to survive and thrive. It helps neurons form new connections with each other, a process called synaptic plasticity that is essential for learning and memory. It helps regulate levels of neurotransmitters, the chemical messengers that allow brain cells to communicate. It helps protect neurons from stress and damage. And it helps clear away toxic proteins that can build up and cause damage over time.
When brain cells become resistant to insulin, all of these functions start to fail. Think of it like a busy office where the computers suddenly stop working. The power is still on. The people are still at their desks. But nothing gets done. Emails don’t go out. Files don’t get saved. Meetings don’t happen. Slowly, the whole operation grinds to a halt.
That’s what happens in the Alzheimer’s brain. Neurons that can’t respond to insulin properly start to malfunction. They can’t form new connections, so learning becomes difficult. They can’t clear away toxic proteins, so plaques and tangles start to build up. They become more vulnerable to stress and damage, so they start to die. Over time, this damage spreads, and the brain begins to shrink.
This discovery created a completely new way of thinking about treating brain diseases. If the problem is insulin resistance in the brain, then maybe medications that help the body overcome insulin resistance could also help the brain. And the most widely used medications for treating insulin resistance are diabetes drugs.
This was the moment when the medical world started to get excited. For decades, we had been looking for treatments for Alzheimer’s disease that targeted the symptoms of the disease, like the amyloid plaques that build up in the brain. Those approaches had mostly failed, with dozens of promising drugs falling short in clinical trials. But now, there was a new hypothesis: what if we could treat Alzheimer’s by targeting metabolism, by helping brain cells use energy more effectively?
The idea made sense. And it had the added advantage of being testable, using medications that were already approved, already widely used, and already known to be safe.
Meet the Main Characters: Metformin and GLP-1 Agonists
Before we dive deeper into the science, it helps to understand the two main classes of diabetes medications that have been the focus of this research. They work in very different ways, and they may affect the brain in different ways too.
The Old Reliable: Metformin
Metformin is something of a legend in the world of diabetes treatment. It was first used in humans in the 1950s in France, and it has been widely available around the world since the 1970s. Today, it’s the most commonly prescribed first-line medication for type 2 diabetes, and it’s on the World Health Organization’s List of Essential Medicines, meaning it’s considered one of the safest and most effective drugs in existence.
What makes metformin so special is how it works. Unlike many other diabetes medications that force the pancreas to pump out more insulin, metformin takes a different approach. Its main effect is on the liver, where it tells the liver to stop producing so much glucose. In people with type 2 diabetes, the liver often churns out glucose even when blood sugar levels are already high, like a factory that keeps producing products even when the warehouse is already overflowing. Metformin puts a stop to that.
But metformin does more than that. It also helps the body’s cells become more sensitive to insulin, which means they can absorb glucose from the bloodstream more effectively. And it has effects throughout the body that reduce inflammation and oxidative stress, two processes that contribute to cell damage in both diabetes and Alzheimer’s.
Metformin is inexpensive, widely available, and has a safety record that spans more than half a century. For most people with type 2 diabetes, it’s the first medication their doctor prescribes. And for many people, it’s the only medication they ever need to keep their blood sugar under control.
The New Kids on the Block: GLP-1 Agonists
GLP-1 receptor agonists are the newer, flashier medications that have been making headlines in recent years. You might know them by names like semaglutide, liraglutide, dulaglutide, or exenatide. They’re sold under brand names like Ozempic, Wegovy, Rybelsus, Victoza, and Trulicity. In the past few years, these drugs have become household names, not just for diabetes but for their dramatic effects on weight loss.
GLP-1 agonists work by mimicking a natural hormone in your body called glucagon-like peptide-1, or GLP-1 for short. This hormone is released from your gut after you eat, and it does several important things. It tells your pancreas to release insulin, which helps lower blood sugar. It tells your liver to stop producing glucose. It slows down how quickly food moves through your stomach, which helps you feel full longer. And it sends signals to your brain that you’ve had enough to eat.
When you take a GLP-1 agonist, you’re essentially giving your body a supercharged version of this natural hormone. The drugs are designed to last much longer in the body than natural GLP-1, so they keep working for days instead of minutes. That’s why most of these medications are injected once a week.
The effects can be dramatic. Many people taking these drugs lose significant amounts of weight, sometimes 15 to 20 percent of their body weight or more. Their blood sugar levels come down. Their blood pressure improves. Their cholesterol numbers get better. In large clinical trials, these drugs have been shown to reduce the risk of heart attack and stroke in people with diabetes.
But perhaps most intriguingly, these drugs also seem to have direct effects on the brain. GLP-1 receptors are found throughout the brain, not just in the areas that control appetite and fullness. They’re present in regions involved in learning, memory, and mood. When these receptors are activated, they can reduce inflammation in the brain, protect neurons from damage, and even encourage the growth of new connections between neurons.
Both of these classes of medications help control blood sugar. But scientists started asking a more interesting question: could they also protect the brain? And if so, which one works better? Which one should doctors prescribe if they’re worried about their patient’s cognitive future?
What the Latest Research Reveals
The scientific community has been buzzing with new studies trying to answer these questions. In the past few years, researchers have published dozens of papers examining the effects of diabetes medications on the brain. And the results have been surprising, sometimes confusing, and always fascinating.
The Case for GLP-1 Agonists
One of the most compelling studies came out in 2025, and it made waves throughout the medical community. This was a massive study that looked at over 87,000 patients with type 2 diabetes in the United States. All of these patients had been diagnosed with diabetes and were taking either GLP-1 agonists or metformin. None of them had dementia at the start of the study.
The researchers followed these patients for several years, watching to see who would go on to develop dementia. They used electronic health records, which meant they could track not just diagnoses but also prescriptions, lab results, and other health information that might affect the results.
When the numbers came in, they were striking. In the group of patients taking GLP-1 agonists, only 2.4 percent developed dementia during the study period. In the metformin group, 4.8 percent developed dementia. That’s double the rate. The difference was statistically significant and held up even after the researchers adjusted for factors like age, sex, race, other medical conditions, and other medications people were taking.
But that wasn’t all. The study also looked at specific types of dementia. The GLP-1 group had lower rates of Alzheimer’s disease specifically, not just overall dementia. They also had lower rates of vascular dementia, the type caused by reduced blood flow to the brain. And perhaps most importantly, they were less likely to die during the study period, regardless of whether they developed dementia.
These numbers tell a compelling story. They suggest that GLP-1 agonists might offer substantial protection against cognitive decline, reducing the risk of dementia by about half compared to metformin. If these results hold up in other studies, it would be one of the most significant findings in dementia research in decades.
The Case for Metformin
But just when it seemed like the case was closed, another study came along that told a different story. This research, published in early 2026 in the journal Communications Medicine, used a completely different approach to answer the same question.
Instead of following patients over time and counting who developed dementia, these researchers used advanced computer methods to analyze the molecular pathways involved in both diabetes and Alzheimer’s. They looked at 39 different diabetes medications and examined how each drug affected the biological processes that are known to go wrong in Alzheimer’s disease.
Their method was sophisticated. They used something called pathway analysis, which looks at networks of genes and proteins that work together to carry out specific functions in cells. They identified which pathways are involved in both diabetes and Alzheimer’s, and then they looked at which drugs affected those pathways most strongly.
Their conclusion surprised many people. According to their analysis, metformin showed the strongest potential for protecting the brain, while semaglutide, one of the most popular GLP-1 drugs, ranked among the least effective. Other GLP-1 agonists ranked higher, but none came close to metformin in terms of their potential to affect the key pathways involved in Alzheimer’s.
The lead researcher, Dr. Andrea Georgiou, explained the findings in an interview. “Our analysis found that metformin showed the strongest potential to protect the brain,” she said. “Its effects work through multiple pathways, including AMPK, insulin, and adipocytokine signaling, all of which influence key Alzheimer’s-related processes.”
AMPK, or AMP-activated protein kinase, is a particularly interesting target. It’s an enzyme that acts like a fuel gauge in your cells, sensing energy levels and triggering responses when energy runs low. Activating AMPK seems to have beneficial effects throughout the body, reducing inflammation, improving insulin sensitivity, and protecting cells from stress. Metformin is known to activate AMPK, and this may be one of the main ways it affects the brain.
So which is it? Does GLP-1 win the brain-protection race, or does metformin come out on top? The answer is more complicated than a simple competition, and understanding why the studies seem to disagree tells us something important about how medical research works.
Understanding the Conflicting Results
To understand why different studies can reach different conclusions, we need to look at what each study actually measured. They were asking different questions, using different methods, and they got different answers. Both might be correct in their own way.
The large study that favored GLP-1 agonists looked at real-world outcomes. It followed actual patients over time and counted who actually developed dementia. This is what researchers call an observational study, and it has both strengths and weaknesses.
The strength is that it shows what happens in real life, not just in a laboratory or a computer simulation. These were real patients, with all the complexity that entails. They had other medical conditions. They took other medications. They lived their lives, made choices, and experienced outcomes. When a drug is associated with a lower rate of dementia in a study like this, that’s a real-world signal that deserves attention.
The weakness is that observational studies can’t prove cause and effect. They can only show associations. Maybe the patients who were prescribed GLP-1 agonists were different from the patients who were prescribed metformin in ways that the researchers couldn’t measure. Maybe they were healthier to begin with. Maybe they had better access to healthcare. Maybe they were more likely to exercise or eat well. Any of these factors could explain the difference in dementia rates, even if the medication itself had no effect.
The study that favored metformin used a completely different approach. Instead of looking at real-world outcomes, it looked at molecular pathways. It used computer models to see which drugs affect the biological processes that are involved in Alzheimer’s. This tells us about potential mechanisms, not necessarily what happens in actual patients.
The strength of this approach is that it gets at the underlying biology. If a drug affects pathways that are known to be important in Alzheimer’s, that’s a reason to think it might be effective. The weakness is that affecting a pathway in a computer model doesn’t guarantee that the drug will actually help patients. Biology is messy, and things that look promising in models sometimes fail when tested in people.
Both approaches have value. And both might be telling us something true. It’s possible that GLP-1 agonists reduce dementia risk in real-world patients, even if metformin looks better in pathway analysis. It’s also possible that metformin has stronger effects on key Alzheimer’s pathways, but those effects don’t translate into better real-world outcomes because of other factors, like the fact that patients who take metformin are often older and sicker than patients who take newer, more expensive drugs.
Dr. Georgiou, who led the metformin study, acknowledged this complexity. “It is important to note,” she said, “that both drug classes may ultimately prove to be beneficial in preventing or treating Alzheimer’s disease. However, they might work through different mechanisms and therefore benefit different patient populations. This is why precision medicine, matching the right drug to the right patient, is so important.”
The Story of One Patient’s Remarkable Journey
Behind the statistics and the scientific papers are real people whose lives have been touched by these discoveries. Their stories help us understand what these findings mean in human terms.
Consider the case of a patient researchers called “EJ” in a 2024 case report. At 80 years old, EJ was a retired mechanical engineer with a doctorate in engineering. He had spent his career designing systems for manufacturing plants, work that required precision, attention to detail, and complex problem-solving skills. His mind had been his greatest tool.
But over the years, EJ’s wife began to notice changes. At first, they were small. He would forget to do simple tasks, like mailing a letter or picking up milk from the store. Then they became more concerning. He would get confused about the order of things. If his wife asked him to put the grocery bags in the car and then go back inside to get the ladder, he would do the first step and completely forget the second. He would stand in the driveway, holding the grocery bags, with no memory of why he was there or what he was supposed to do next.
EJ had abnormal blood sugar levels for fourteen years before he was diagnosed with mild cognitive impairment. His glucose levels fluctuated wildly, often above 200 mg/dL, far higher than the normal range. Despite this, his doctors had told him that his “overall health looks very good,” focusing on his blood pressure and cholesterol numbers while missing the early signs of cognitive decline.
Then EJ became part of a research study that was testing something unusual: delivering insulin directly to the brain through a nasal spray. The idea behind this approach is that when you take insulin by injection, very little of it reaches the brain. The blood-brain barrier, a protective layer that surrounds the brain, keeps most things out. But when you spray insulin into the nose, some of it can travel along the olfactory nerve and reach the brain directly.
EJ started using the nasal insulin spray every day. And over nine months, something remarkable happened.
Brain scans showed that his gray matter volume increased. In Alzheimer’s disease, the brain typically shrinks as neurons die. But EJ’s brain was actually getting larger, suggesting that some of the damage was being reversed. The levels of beta-amyloid, the protein that forms the characteristic plaques in Alzheimer’s disease, went down. His memory test scores improved. He started performing better on tests of executive function, the set of mental skills that include working memory, flexible thinking, and self-control.
But perhaps the most touching changes were the ones his family noticed. EJ started making socially appropriate comments again, the kind of subtle conversational moves that require understanding context and reading other people’s emotions. He started showing affection to his wife in ways he hadn’t for years. He engaged with his grandchildren, asking them about their lives and remembering what they told him. His family felt like they were getting him back.
While this case involved insulin rather than metformin or GLP-1 drugs, it illustrates the same principle. Medications that affect insulin and metabolism in the body can have powerful effects on the brain. And sometimes, those effects can be dramatic enough to change the course of someone’s life.
Beyond Alzheimer’s: Effects on Parkinson’s and Other Brain Diseases
The brain benefits of diabetes medications might extend beyond memory loss and Alzheimer’s disease. New research suggests they could also affect the risk of other neurodegenerative conditions, including Parkinson’s disease.
Parkinson’s is the second most common neurodegenerative disease after Alzheimer’s, affecting more than 10 million people worldwide. It’s characterized by the death of dopamine-producing neurons in a part of the brain called the substantia nigra. This leads to the classic symptoms of Parkinson’s: tremors, stiffness, slowness of movement, and problems with balance and coordination. But Parkinson’s also causes non-motor symptoms, including depression, anxiety, and cognitive decline.
A large study published in early 2026 looked at over 92,000 patients with type 2 diabetes. Some were taking GLP-1 agonists, and some were taking metformin. The researchers followed them over time to see who developed Parkinson’s disease.
The overall results were not dramatic. When the researchers looked at the entire study period, there wasn’t much difference between the two groups. But when they looked more closely at specific time windows, something interesting emerged.
Between years five and ten of follow-up, the GLP-1 group had a 44 percent lower risk of developing Parkinson’s compared to the metformin group. That’s a substantial reduction, comparable to the reduction in dementia risk seen in the larger study.
What does this tell us? It suggests that the brain-protective effects of these medications might take time to show up. It’s not like taking an aspirin for a headache, where you feel better within an hour. It’s more like fertilizing a garden. The benefits come gradually, over months and years, as the medication works to protect cells from damage and support their function.
The researchers who conducted the Parkinson’s study proposed that GLP-1 drugs might have what they called a “delayed neuroprotective effect.” In plain English, that means the drugs might be quietly protecting brain cells from damage in ways that only become visible after several years of treatment.
This pattern fits with what we know about how these drugs work. They don’t just affect blood sugar. They also reduce inflammation, which is a slow, chronic process that damages cells over time. They improve how cells use energy, which affects their ability to function and survive. They may even encourage the growth of new connections between neurons, which takes time to develop.
If you’re taking one of these drugs, the benefits for your brain might not be immediately apparent. But over the course of years, the cumulative effect could be substantial.
How Do These Drugs Actually Protect the Brain?
Now that we’ve seen the evidence that diabetes medications can affect the brain, the next question is: how? What are the actual biological mechanisms that allow a drug designed to lower blood sugar to protect the brain from diseases like Alzheimer’s and Parkinson’s?
Scientists have identified several possible mechanisms, and it’s likely that all of them play a role. Think of these as different paths that lead to the same destination. Some medications might travel one path, others might travel a different path, but they all end up providing some protection for the brain.
Reducing Inflammation
One of the most important mechanisms is reducing inflammation. Inflammation is the body’s natural response to injury or infection. In the short term, it’s helpful and necessary. But when inflammation becomes chronic, it can cause damage throughout the body, including the brain.
In the Alzheimer’s brain, there is widespread inflammation. Microglia, the brain’s immune cells, become activated and start releasing inflammatory molecules that can damage nearby neurons. This inflammation is thought to contribute to the progression of the disease, speeding up the loss of brain cells and function.
Both metformin and GLP-1 drugs have been shown to reduce inflammation throughout the body. They lower levels of inflammatory molecules like C-reactive protein, interleukin-6, and tumor necrosis factor-alpha. And this anti-inflammatory effect appears to extend to the brain. In animal studies, both classes of drugs have been shown to reduce the activation of microglia and lower levels of inflammatory molecules in the brain.
Improving Energy Use
Another important mechanism is improving how brain cells use energy. The brain is an energy hog. It makes up only about 2 percent of your body weight, but it consumes about 20 percent of your body’s energy. Brain cells need a constant supply of glucose to function properly.
When brain cells become resistant to insulin, they struggle to take up glucose from the bloodstream. It’s like having a full tank of gas but a broken fuel line. The energy is there, but the cells can’t access it. Over time, this energy deficit causes cells to malfunction and eventually die.
Both metformin and GLP-1 drugs help improve insulin sensitivity throughout the body, including in the brain. By making brain cells more responsive to insulin, they help ensure that these cells can get the energy they need to function properly.
Clearing Toxic Proteins
In Alzheimer’s disease, two types of toxic proteins build up in the brain: beta-amyloid and tau. Beta-amyloid forms plaques between neurons, while tau forms tangles inside neurons. Both are thought to contribute to the death of brain cells.
Some studies suggest that GLP-1 drugs help the brain clear out these toxic proteins more effectively. In animal models of Alzheimer’s, treatment with GLP-1 agonists has been shown to reduce levels of both beta-amyloid and tau. This may happen because GLP-1 drugs enhance the brain’s natural clearance mechanisms, helping it get rid of waste products that would otherwise accumulate and cause damage.
Protecting Blood Vessels
Diabetes damages blood vessels throughout the body, and the brain is no exception. High blood sugar can damage the delicate lining of blood vessels, making them more likely to become narrowed or blocked. When this happens in the brain, it can lead to vascular dementia, the second most common type of dementia after Alzheimer’s.
Both metformin and GLP-1 drugs have cardiovascular benefits that help protect blood vessels. They improve blood pressure, reduce inflammation in blood vessel walls, and may even help reverse some of the damage caused by high blood sugar. By protecting the blood vessels that supply the brain, these medications help ensure that brain cells get the oxygen and nutrients they need.
Encouraging New Brain Cell Growth
Perhaps the most exciting potential mechanism is that some of these drugs might actually encourage the growth of new brain cells. For a long time, scientists believed that adult brains couldn’t grow new neurons. We now know that’s not true. The adult brain does produce new neurons, particularly in a region called the hippocampus, which is crucial for learning and memory.
Some research suggests that metformin might promote this process of neurogenesis. In animal studies, metformin has been shown to increase the production of new neurons in the hippocampus. This could help the brain compensate for damage and maintain function even as some cells are lost.
This is still an area of active research, and it’s not yet clear whether the same effects occur in humans. But it’s an intriguing possibility that could help explain why these drugs seem to have such profound effects on cognitive function in some patients.
The Importance of the Right Fit
One of the most important lessons from this research is that not all patients are the same, and not all medications work the same for everyone. What works for one person might not work for another, and what causes side effects in one person might be perfectly well tolerated by someone else.
The researchers who found that metformin showed the strongest brain-protective potential emphasized the importance of what they called “precision medicine.” This means choosing treatments based on an individual patient’s specific characteristics, rather than assuming one size fits all.
What might these characteristics include? Age is one factor. Older patients might respond differently to medications than younger patients. Genetics is another. Some people have genetic variations that affect how they metabolize certain drugs, which can influence both effectiveness and side effects. The severity and duration of diabetes might matter too. Someone who has had diabetes for 20 years might have different needs than someone who was diagnosed last year.
Other medical conditions also play a role. Someone with kidney disease might not be able to take metformin, which can accumulate in the kidneys and cause problems. Someone with a history of certain types of thyroid cancer might not be a good candidate for GLP-1 drugs, which have been linked to a small increased risk of thyroid tumors.
Even lifestyle factors matter. Someone who struggles with weight might benefit more from a GLP-1 drug that promotes weight loss, while someone who is already at a healthy weight might do better with metformin.
The ongoing LIGHT-MCI trial, which began in 2022 and is expected to finish in 2026, is directly comparing different diabetes medications to see which works best for improving cognitive function in patients with mild cognitive impairment. This study is looking at three different drugs: liraglutide, which is a GLP-1 agonist; empagliflozin, which is an SGLT2 inhibitor; and linagliptin, which is a DPP-4 inhibitor.
Each of these drugs works through a different mechanism. Liraglutide mimics GLP-1, the hormone that controls appetite and insulin release. Empagliflozin works by causing the kidneys to excrete excess glucose in the urine. Linagliptin works by blocking an enzyme that breaks down GLP-1, allowing the body’s natural GLP-1 to stay active longer.
By comparing these different approaches head-to-head, the LIGHT-MCI trial will help doctors understand which medications are most effective for patients at risk of cognitive decline. And because the trial is looking at patients with mild cognitive impairment rather than full-blown dementia, it may identify treatments that can be started early, before too much damage has occurred.
What This Means for Patients Today
If you or someone you love has type 2 diabetes, you might be reading this and wondering what to do with the information. Should you ask your doctor to switch your medication? Should you be worried if you’re taking metformin instead of a GLP-1 drug? Should you be trying to get a prescription for one of these newer medications even if your blood sugar is well controlled?
The short answer is: don’t make any changes without talking to your doctor.
These medications are prescribed for specific reasons, and they have different benefits and risks. Metformin has been used for more than half a century, and its safety profile is extremely well understood. It remains the first-line treatment for most people with type 2 diabetes, and for good reason. It’s effective, inexpensive, and generally well tolerated.
GLP-1 drugs are newer, and while they have impressive benefits, they also have some drawbacks. They’re much more expensive than metformin, often costing hundreds or even thousands of dollars per month. They’re typically given as injections, which some people find inconvenient or uncomfortable. And they can cause side effects, particularly nausea, vomiting, and diarrhea, especially when people first start taking them.
What these findings do suggest is that when you and your doctor are choosing diabetes medications, the potential brain benefits should be part of the conversation. If you’re at high risk for dementia, perhaps because of family history or because you already have mild cognitive impairment, your doctor might consider choosing a medication that offers brain protection in addition to blood sugar control.
Dr. Ross Dunne, who is leading part of a major GLP-1 trial in the UK, put it this way in a recent interview: “Semaglutide is one of a host of medications already licensed for other conditions which may play a role in reducing the progression of early Alzheimer’s. What’s exciting about this approach is that these are drugs we already know are safe. We’re not starting from scratch.”
This is an important point. When researchers test a brand-new drug for Alzheimer’s, they have to start with phase 1 trials to establish safety, then phase 2 trials to find the right dose, then phase 3 trials to test effectiveness. This process can take a decade or more and cost billions of dollars. When researchers test a drug that’s already approved for another condition, they can skip many of those early steps. They already know the drug is safe. They already know the right dose. They can go straight to testing whether it works for the new condition.
This means that if these drugs prove effective for Alzheimer’s or Parkinson’s, they could be available to patients much faster than a brand-new drug. It could be a matter of years rather than decades.
The Exciting Future of Drug Repurposing
One of the most exciting aspects of this research is that it represents a broader trend in medicine called “drug repurposing.” Instead of spending billions of dollars and decades developing new drugs from scratch, researchers are looking at existing medications to see what else they can do.
The advantages of this approach are enormous. These drugs have already been tested for safety in thousands of people, often over many years. Their side effects are well understood. Their manufacturing processes are already established. And because they’re already approved for other uses, if they prove effective for a new condition, they can be prescribed right away, without waiting for a lengthy approval process.
Drug repurposing has already had some notable successes. Aspirin, originally developed as a pain reliever, is now used to prevent heart attacks and strokes. Thalidomide, which caused a tragedy when used in pregnancy, was later repurposed as a treatment for multiple myeloma, a type of blood cancer. Sildenafil, originally developed as a treatment for high blood pressure and angina, became the blockbuster drug Viagra.
Now, diabetes medications may be next in line. The EVOKE trial, currently underway in Greater Manchester and other locations around the world, is testing exactly this concept. This phase 3 clinical trial is looking at whether semaglutide can slow the progression of early-stage Alzheimer’s disease. About 3,500 participants are taking part globally over a three-year period.
Participants in the trial take either semaglutide or a placebo every day. Neither the patients nor the researchers know who is getting the real drug. At the end of the study, they’ll compare cognitive test results between the two groups to see if the drug made a difference.
The trial is designed to detect even modest effects. If semaglutide can slow the progression of Alzheimer’s by 20 or 30 percent, that would be a major advance. Currently, there are no treatments that can stop or reverse Alzheimer’s, and the few treatments that exist have very modest effects. A drug that could slow the disease’s progression, even a little, would be welcomed by patients and families who currently have very few options.
If the results are positive, it could revolutionize how we treat Alzheimer’s. Instead of having no good treatments for the disease, we might have a safe, affordable, widely available medication that can help slow its progression. And because the drug is already approved for diabetes, doctors could start prescribing it for Alzheimer’s right away, without waiting for a new approval process.
The Bigger Picture: Lifestyle Still Matters
While the discovery that diabetes medications can affect the brain is exciting, it’s important not to lose sight of the bigger picture. These medications work best when combined with healthy lifestyle choices. They’re not a magic bullet, and they can’t undo years of unhealthy habits.
What you eat affects your brain. Diets high in processed foods, sugar, and unhealthy fats have been linked to higher rates of cognitive decline. Diets rich in vegetables, fruits, whole grains, and healthy fats, like the Mediterranean diet, have been linked to lower rates of cognitive decline and dementia.
Exercise improves insulin sensitivity throughout your body, including your brain. Regular physical activity has been shown to increase the size of the hippocampus, the brain region involved in memory formation. It also reduces inflammation, improves blood flow to the brain, and promotes the growth of new brain cells.
Sleep helps your brain clear out toxic proteins. During sleep, your brain activates something called the glymphatic system, which acts like a washing machine, flushing out waste products that build up during the day. People who don’t get enough sleep have higher levels of beta-amyloid in their brains, the protein that forms the plaques of Alzheimer’s disease.
Managing stress protects your brain cells from damage. Chronic stress raises levels of cortisol, a hormone that can damage the hippocampus and impair memory. People who experience high levels of stress over long periods have higher rates of cognitive decline and dementia.
Staying socially connected is also crucial. People who have strong social networks and engage regularly with others have lower rates of cognitive decline than people who are isolated. Social engagement challenges the brain, requiring it to process complex information, interpret social cues, and respond appropriately.
The case of EJ, the retired engineer who received intranasal insulin, illustrates the importance of these lifestyle factors. His improvement likely depended on more than just the medication. His family’s support was crucial. His engagement in activities, even as his cognitive function declined, helped maintain his brain function. His overall health, supported by good nutrition and medical care, provided the foundation that allowed the medication to work.
If you have diabetes or are at risk for cognitive decline, the most important things you can do are:
Work with your doctor to keep your blood sugar well controlled. High blood sugar damages blood vessels and nerves throughout the body, including the brain. Even if you’re taking medication, monitoring your blood sugar and making adjustments as needed is essential.
Stay physically active. Aim for at least 150 minutes of moderate exercise per week, like brisk walking, swimming, or cycling. Even small amounts of activity are better than none.
Eat a balanced diet rich in vegetables, fruits, and healthy proteins. The Mediterranean diet, which emphasizes olive oil, fish, nuts, and plenty of vegetables, has been linked to lower rates of cognitive decline.
Get enough sleep. Most adults need seven to nine hours of sleep per night. If you have sleep apnea or other sleep disorders, getting treatment can help protect your brain.
Stay socially connected. Make time for friends and family. Join clubs or groups that interest you. Volunteer in your community.
Keep your brain active. Read books, do puzzles, learn new skills, take classes. Challenging your brain helps build cognitive reserve, which can help you maintain function even if some brain cells are damaged.
These habits create the foundation that medications can build upon. No drug can replace the benefits of a healthy lifestyle, and no healthy lifestyle can completely eliminate the risk of cognitive decline in someone with diabetes. But together, medication and lifestyle can be powerful partners in protecting your brain.
What Scientists Are Still Trying to Figure Out
For all the exciting discoveries, there’s still much we don’t know. Scientists are working to answer several important questions, and the answers will shape how we use these medications in the future.
Why do different studies sometimes disagree?
As we saw with the metformin versus GLP-1 debate, different study designs can produce different results. Large, long-term trials that directly compare treatments head-to-head will help clarify the picture. The EVOKE trial and other ongoing studies will provide more definitive answers.
But even when those results come in, there will likely be nuances. A drug that works well for one group of patients might not work as well for another. A drug that works well for preventing dementia might not work as well for treating it once it’s already started. These are the kinds of details that take time to work out.
Who benefits most?
Not every patient will get the same benefit from these medications. Researchers are trying to figure out which patients are most likely to experience brain protection. Factors like age, genetics, how long they’ve had diabetes, and what other health conditions they have might all play a role.
One area of active research is the role of genetics. Some people carry a gene called APOE4 that significantly increases their risk of Alzheimer’s. These individuals might be particularly good candidates for brain-protective medications, or they might be less responsive to them. Researchers are trying to find out.
How long do you need to take the medication?
The Parkinson’s study suggested that benefits might take five to ten years to show up. Does that mean you need to take these medications for years to protect your brain? Or is there a window of opportunity where treatment is most effective?
This is an important question because these medications aren’t free of side effects. Taking them for years increases the cumulative risk of side effects and adds to the cost of healthcare. If a shorter course of treatment could provide lasting protection, that would be ideal. But we don’t know yet whether that’s possible.
What about side effects?
Both metformin and GLP-1 drugs have side effects that need to be considered. Metformin can cause digestive issues, including diarrhea, nausea, and stomach pain. In rare cases, it can cause a serious condition called lactic acidosis, where lactic acid builds up in the blood. This is more common in people with kidney problems or other medical conditions.
GLP-1 drugs can cause nausea, vomiting, and diarrhea, especially when people first start taking them. There have been reports of a small increased risk of certain thyroid tumors with some GLP-1 drugs, though the absolute risk is very low. There have also been reports of gallbladder disease and pancreatitis in people taking these drugs.
Researchers need to balance the potential brain benefits against these risks. For someone at very high risk of dementia, even a small risk of side effects might be worth taking. For someone at lower risk, the balance might tip the other way.
Can these medications help people who don’t have diabetes?
If these drugs protect the brain partly by improving insulin sensitivity, could they help people who have normal blood sugar but are at risk for Alzheimer’s? This is a question researchers are beginning to explore.
There’s some evidence that insulin resistance in the brain can occur even in people who don’t have diabetes. These people might still benefit from medications that improve insulin sensitivity. But it’s also possible that the drugs work primarily through their effects on blood sugar, and people with normal blood sugar might not get the same benefit.
The EVOKE trial is recruiting people with early Alzheimer’s, regardless of whether they have diabetes. If the results are positive, it would suggest that the brain-protective effects of these drugs extend beyond people with diabetes.
What about other diabetes medications?
Metformin and GLP-1 agonists aren’t the only diabetes medications out there. There are several other classes, including SGLT2 inhibitors, DPP-4 inhibitors, and thiazolidinediones. Some of these might also have brain-protective effects.
The LIGHT-MCI trial is comparing liraglutide (a GLP-1 agonist), empagliflozin (an SGLT2 inhibitor), and linagliptin (a DPP-4 inhibitor). This will give us a better sense of whether other classes of diabetes medications offer brain benefits. It’s possible that SGLT2 inhibitors, which work by causing the kidneys to excrete excess glucose, might have different effects on the brain than GLP-1 agonists or metformin.
A New Way of Thinking About Brain Health
Perhaps the most important change these discoveries represent is a new way of thinking about brain health. For a long time, we treated the brain as separate from the rest of the body. Neurologists took care of the brain, endocrinologists took care of diabetes, and cardiologists took care of the heart. Patients saw different doctors for different problems, and those doctors often didn’t talk to each other.
We now know that these systems are deeply connected. What happens in your body affects your brain. Your metabolism influences your memory. Your blood sugar levels can determine whether you keep your mental sharpness as you age.
This understanding is leading to more integrated approaches to healthcare. Some medical centers are now creating “brain health” clinics that bring together neurologists, endocrinologists, cardiologists, and other specialists to care for patients as whole people, not collections of separate conditions.
Doctors are starting to consider how the medications they prescribe for one condition might affect other parts of the body. A cardiologist might choose a blood pressure medication that also has benefits for the brain. An endocrinologist might consider a patient’s family history of Alzheimer’s when choosing a diabetes medication. A primary care doctor might screen for cognitive impairment in patients with diabetes, even if those patients aren’t complaining about memory problems.
Patients are starting to understand that caring for their overall health is one of the best things they can do for their brain. They’re asking different questions at their doctor visits. Instead of just asking about their blood sugar numbers, they’re asking about how their diabetes treatment might affect their memory in the long run. Instead of just worrying about their heart, they’re thinking about their brain too.
The story of Margaret, the retired teacher we met at the beginning of this article, illustrates this new thinking. When Sarah Chen looked back at Margaret’s records, she realized that the improvement in Margaret’s mental sharpness coincided with a change in her medication. Her previous doctor had switched her from metformin to a GLP-1 agonist about two years ago, hoping to help her lose some weight.
Sarah couldn’t be sure that the medication change caused Margaret’s crossword puzzle success. But she made a note in Margaret’s chart to continue the GLP-1 medication and to track her cognitive function more closely in the future. She also started asking her other patients about their memory and thinking, not just their blood sugar. She started considering brain health as part of diabetes care, not as something separate.
Sometimes, the most important medical discoveries don’t happen in laboratories with expensive equipment and white-coated researchers. They happen in doctor’s offices, with patients like Margaret, when observant clinicians notice something unexpected and start asking questions.
Hope for the Future
As we look to the future, there’s reason for optimism. The combination of large observational studies, advanced computer modeling, and carefully controlled clinical trials is giving us a clearer picture than ever before of how diabetes medications affect the brain.
The ongoing clinical trials, like EVOKE and LIGHT-MCI, will provide answers in the next few years. If they show positive results, we could be on the verge of having new tools to fight Alzheimer’s disease, a condition that currently has very limited treatment options.
But even before those results come in, there’s something we can all take away from this research. The connection between metabolism and brain health is real. What you do to keep your body healthy today will help protect your brain tomorrow.
Whether it’s controlling your blood sugar, eating well, staying active, or simply staying curious and engaged with the world around you, every positive choice adds up. You’re not just protecting your heart or your pancreas. You’re protecting the most precious organ you have: your brain.
And for people like Margaret, that means more than just crossword puzzles. It means staying connected to family and friends. It means maintaining independence. It means living a fuller, richer life for longer. It means having more time with the people they love, doing the things they enjoy, being the person they’ve always been.
That’s a discovery worth celebrating. And it’s a discovery that gives hope to millions of people who are facing the challenges of diabetes, cognitive decline, or both.
The science will continue to evolve. New studies will come out, and our understanding will deepen. But the fundamental message is already clear: the brain and the body are not separate. Caring for your body is caring for your brain. And sometimes, the most powerful treatments for the brain might come from unexpected places.
Key Takeaways
Type 2 diabetes significantly increases the risk of Alzheimer’s disease. This connection is so strong that some researchers have begun calling Alzheimer’s “type 3 diabetes.” The brains of people with Alzheimer’s often show signs of insulin resistance, similar to what happens in the bodies of people with type 2 diabetes. This suggests that treatments that improve insulin sensitivity might also protect the brain.
Common diabetes medications show potential brain-protective effects. Both metformin, the old standby, and GLP-1 agonists, the newer class of drugs, have been studied for their effects on the brain. Research results vary on which medication works best, and both may have benefits for different patients.
A major 2025 study found that GLP-1 agonists were associated with half the dementia rate compared to metformin. In that study of over 87,000 patients, 2.4 percent of those taking GLP-1 agonists developed dementia, compared to 4.8 percent of those taking metformin. The GLP-1 group also had lower rates of Alzheimer’s specifically and were less likely to die during the study period.
A 2026 computer-based study ranked metformin highest for Alzheimer’s protection. Using advanced pathway analysis, researchers found that metformin affected more of the molecular pathways involved in Alzheimer’s than any other diabetes medication. Semaglutide, one of the most popular GLP-1 drugs, ranked among the least effective in this analysis.
These medications may protect the brain through multiple mechanisms. They reduce inflammation, which damages brain cells over time. They improve how cells use energy, helping brain cells function properly. They may help clear toxic proteins like beta-amyloid and tau. They protect the blood vessels that supply the brain. And some research suggests they might even encourage the growth of new brain cells.
GLP-1 drugs may also lower Parkinson’s risk. A 2026 study found that between years five and ten of treatment, people taking GLP-1 agonists had a 44 percent lower risk of developing Parkinson’s disease compared to those taking metformin. This suggests the brain-protective effects of these medications may take time to become apparent.
Ongoing clinical trials are testing whether these drugs can slow early-stage Alzheimer’s progression. The EVOKE trial is testing semaglutide in about 3,500 people with early Alzheimer’s. The LIGHT-MCI trial is comparing liraglutide, empagliflozin, and linagliptin in people with mild cognitive impairment. Results from these trials are expected in the next few years.
The choice of medication should be personalized. Different patients may respond differently to different medications. Factors like age, genetics, other medical conditions, and lifestyle should all be considered. Patients should discuss the potential brain benefits of diabetes medications with their doctors, along with the risks and costs.
Lifestyle factors remain crucial. No medication can replace the benefits of a healthy lifestyle. Eating well, staying physically active, getting enough sleep, managing stress, staying socially connected, and keeping the brain engaged all help protect against cognitive decline.
The concept of drug repurposing offers hope for faster treatments. Because diabetes medications are already approved and known to be safe, if they prove effective for Alzheimer’s or Parkinson’s, they could be available to patients much faster than brand-new drugs. This could dramatically speed up the process of bringing new treatments to patients who need them.
The future of brain health looks brighter than ever. As research continues, we’re learning more about the connections between metabolism and brain function. This knowledge is leading to new approaches to preventing and treating cognitive decline, giving hope to millions of people and their families.
